

\$6,017,000



Follow-On

Lead Placement Agent

OCTOBER 2022

## Roth Capital Partners Acted as Lead Placement Agent for Panbela Therapeutics, Inc. (Nasdaq:PBLA) in its \$6 Million Follow-On

### For more information please contact:

#### Investment Banking

**James Antonopoulos**  
Managing Director &  
Head of Healthcare  
Investment Banking  
(646) 358-1906  
[jantonopoulos@roth.com](mailto:jantonopoulos@roth.com)

**Aparna Beeram**  
Vice President  
(646) 358-1912  
[abeeram@roth.com](mailto:abeeram@roth.com)

#### Equity Capital Markets

**Aaron Gurewitz**  
Head of Equity  
Capital Markets  
(949) 720-5703  
[agurewitz@roth.com](mailto:agurewitz@roth.com)

**Nazan Akdeniz**

### Transaction Information

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced the pricing of a public offering of (i) 20,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 30,150,000 shares of its common stock (the "Public Warrants") at a purchase price of \$0.30 per share and associated Public Warrant. The Public Warrants will have an exercise price of \$0.30 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering closed on October 4, 2022.

Roth Capital Partners acted as lead placement agent for the offering.

### About Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela's lead assets are Ivospemin (SBP-101) and Flynpovi. For further information about the Company, please

Senior Vice President  
(949) 720-5740  
[nakdeniz@roth.com](mailto:nakdeniz@roth.com)

**Lou Ellis**  
Senior Vice President  
(949) 720-5739  
[lellis@roth.com](mailto:lellis@roth.com)

visit [www.Panbela.com](http://www.Panbela.com). (Source: Company Website 10.4.22)

### **About Roth Capital Partners**

Roth Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, Roth is privately-held and employee owned, and maintains offices throughout the U.S. For more information on Roth, please visit [www.roth.com](http://www.roth.com).

---

[About Roth](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading](#)  
[Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

---

Date of Announcement: 10.13.22

The material, information and facts discussed in this announcement other than the information regarding Roth Capital Partners, LLC ("Roth") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2022.



**ROTH Capital Partners, LLC**

888 San Clemente Drive, Newport Beach CA, 92660 | Member SIPC / FINRA | [www.roth.com](http://www.roth.com)